• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by IceCure Medical Ltd.

    5/6/26 4:29:51 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care
    Get the next $ICCM alert in real time by email
    6-K 1 ea0289537-6k_icecure.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of May 2026

     

    Commission File Number: 001-40753

     

    ICECURE MEDICAL Ltd.

    (Translation of registrant’s name into English)

     

    7 Ha’Eshel St., PO Box 3163

    Caesarea, 3079504 Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F      ☐ Form 40-F

     

     

     

     

     

     

    CONTENTS

     

    As previously disclosed, on July 5, 2021, IceCure Medical Ltd. (the “Company”) was informed that a motion to certify a claim as a class action was filed by a purported shareholder of the Company in the Tel Aviv District Court (the “Court”) against the Company, certain members of its board of directors, its controlling shareholder and certain investors who participated in a private placement approved by the Company’s shareholders on March 7, 2021.

     

    The motion alleges, among other things, that the private placement was conducted at a significant discount to the Company’s share price, that the share price did not reflect certain material information allegedly in the Company’s possession at the time, and that there were alleged defects in the approval process of the private placement.

     

    Following evidentiary proceedings and submission of briefs by the parties, on May 5, 2026, the Court issued a decision approving the motion to certify the proceeding as a class action against the Company, its officers and directors, its controlling shareholder and, to a more limited extent, certain investors who participated in the private placement. The Court also approved the certification of two plaintiff classes, appointed the applicant as the representative plaintiff and approved the causes of action set forth in the decision.

     

    The Company respectfully disagrees with the Court’s decision and continues to believe that the claims are without merit. The Company is currently reviewing the decision, is considering its next steps, including the possibility of filling a motion for rehearing or otherwise seeking further review, and intends to defend itself vigorously.

     

    This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046  and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission (the “SEC”), to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Forward-Looking Statements:

     

    This Report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, the Company is using forward-looking statements when it discusses its expectations with respect to the outcome of the legal proceedings described above, potential next steps and intent to defend itself vigorously. All statements other than statements of historical facts included in this Report are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include the risks and uncertainties described in the Company’s annual report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      IceCure Medical Ltd.
         
    Date: May 6, 2026 By:  /s/ Eyal Shamir
        Eyal Shamir
        Chief Executive Officer

     

     

    2

     

     

    Get the next $ICCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICCM

    DatePrice TargetRatingAnalyst
    2/2/2022$5.65Buy
    Brookline Capital
    9/22/2021$14.50Buy
    Alliance Global Partners
    More analyst ratings

    $ICCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by VP, R&D & Engineering Muchnik Naum

    4 - IceCure Medical Ltd. (0001584371) (Issuer)

    5/18/26 8:01:55 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    New insider Peleg Meir claimed ownership of 400,000 units of Ordinary shares (SEC Form 3)

    3 - IceCure Medical Ltd. (0001584371) (Issuer)

    5/18/26 8:00:34 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Tsimerman Ronen

    4 - IceCure Medical Ltd. (0001584371) (Issuer)

    5/18/26 8:01:20 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    SEC Filings

    View All

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    6/18/26 4:47:30 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    6/2/26 8:45:20 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by IceCure Medical Ltd.

    6-K - IceCure Medical Ltd. (0001584371) (Filer)

    5/19/26 8:45:22 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brookline Capital initiated coverage on Icecure Medical with a new price target

    Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

    2/2/22 11:13:08 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Alliance Global Partners initiated coverage on Icecure Medical with a new price target

    Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

    9/22/21 8:10:09 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

    Published in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the world's top 20 medical device companiesCAESAREA, Israel, June 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tu

    6/23/26 8:10:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

    CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase up to 1,833,334 ordinary shares (the "Series E Warrants," and together with the Seri

    6/17/26 1:14:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

    DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones NeOnc (NASDAQ:NTHI) is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, the company's ora

    6/17/26 10:37:33 AM ET
    $CLPT
    $ICCM
    $NTHI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ICCM
    Financials

    Live finance-specific insights

    View All

    IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

    Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearanceAccelerating adoption of ProSense® driven by several growth catalysts, including FDA clearance, expanding reimbursement framework, media coverage, growing body of clinical data and recommendation of cryoablation for breast cancer in leading clinical guidelinesConference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, May 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology t

    5/12/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

    The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in

    4/21/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Reports 2025 Full Year Financial & Operational Results

    Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectivelyStrong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customersIceCure Applies to Expand Regulatory Approval in Canada for ProSense® Cryoablation to Include the Treatment of Low-Risk Breast Cancer  Conference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the

    3/17/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Leadership Updates

    Live Leadership Updates

    View All

    IceCure Appoints Meir Peleg as Chief Financial Officer

    Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the appointment of Mr. Meir Peleg as its Chief Financial Officer ("CFO"), effective May 17, 2026. The appointment comes as IceCure is

    3/24/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

    Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that after nearly a decade of service with IceCure, Chief Financial Officer Ronen Tsimerman has informed the Company of his decision to leave the Company to pursue new opportunities. The Company has initiated a search for a new Chief Financial Officer and has identified compelling candidates with significant experience commercializing disruptive technolo

    2/9/26 4:30:00 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America

    Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

    8/28/23 8:00:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    $ICCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IceCure Medical Ltd.

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    11/14/24 9:38:43 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    2/14/23 8:46:31 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by IceCure Medical Ltd. (Amendment)

    SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

    1/24/23 5:04:22 PM ET
    $ICCM
    Medical/Dental Instruments
    Health Care